Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-28 7:57 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Adjuvant Global Health Technology Fund, L.P. | 2,373,500 7.900% |
-100,000 (-4.04%) |
Filing History |
| 2025-02-14 6:27 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
RA Capital Management, L.P. | 0 0.000% |
-1,999,997 (Position Closed) |
Filing History |
| 2025-02-14 4:44 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 0 0.000% |
-1,555,118 (Position Closed) |
Filing History |
| 2025-02-14 4:30 pm Sale |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Brii Biosciences Limited | 927,201 3.100% |
-121,278 (-11.57%) |
Filing History |
| 2025-02-14 11:07 am Unchanged |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Frazier Life Sciences Public Fund, L.P. | 0 0.000% |
0 (Unchanged) |
Filing History |
| 2025-02-13 4:30 pm Purchase |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Easom Eric | 1,893,132 6.200% |
320,962 (+20.42%) |
Filing History |
| 2025-02-13 4:28 pm Unchanged |
2024-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 5,749,432 19.200% |
0 (Unchanged) |
Filing History |
| 2024-11-14 4:29 pm Sale |
2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX |
BIOTECHNOLOGY VALUE FUND L P | 0 0.000% |
-1,563,963 (Position Closed) |
Filing History |
| 2024-11-14 4:16 pm Sale |
2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX |
Citadel Advisors LLC | 22 0.000% |
-1,556,820 (-100.00%) |
Filing History |
| 2024-11-13 4:25 pm Sale |
2024-09-30 | 13G | AN2 Therapeutics, Inc. ANTX |
TCG Crossover GP I, LLC | 1,555,118 5.200% |
-1,123,091 (-41.93%) |
Filing History |
| 2024-08-28 4:02 pm Sale |
2024-08-26 | 13G | AN2 Therapeutics, Inc. ANTX |
Octagon Capital Advisors LP | 0 0.000% |
-3,009,927 (Position Closed) |
Filing History |
| 2024-08-14 9:00 pm Purchase |
2024-08-14 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 5,749,432 19.300% |
1,500,000 (+35.30%) |
Filing History |
| 2024-08-13 5:40 pm Sale |
2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX |
RA Capital Management, L.P. | 1,999,997 6.700% |
-3,551,298 (-63.97%) |
Filing History |
| 2024-08-12 4:48 pm Purchase |
2024-08-09 | 13G | AN2 Therapeutics, Inc. ANTX |
BML Investment Partners, L.P. | 4,249,432 14.200% |
4,249,432 (New Position) |
Filing History |
| 2024-07-03 08:02 am Purchase |
2024-06-13 | 13G | AN2 Therapeutics, Inc. ANTX |
Octagon Capital Advisors LP | 3,009,927 10.100% |
3,009,927 (New Position) |
Filing History |
| 2024-04-10 4:44 pm Purchase |
2024-04-03 | 13G | AN2 Therapeutics, Inc. ANTX |
Frazier Life Sciences Public Fund, L.P. | 1,488,889 5.000% |
1,488,889 (New Position) |
Filing |
| 2024-02-14 5:01 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
RA Capital Management, L.P. | 5,551,295 18.700% |
1,777,778 (+47.11%) |
Filing History |
| 2024-02-14 4:57 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Citadel Advisors LLC | 1,556,842 5.200% |
219,849 (+16.44%) |
Filing History |
| 2024-02-14 2:29 pm Purchase |
2023-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
PFIZER INC PFE |
1,362,499 4.580% |
1,362,499 (New Position) |
Filing History |
| 2024-02-13 5:11 pm Purchase |
2022-12-31 | 13G | AN2 Therapeutics, Inc. ANTX |
Easom Eric | 1,572,170 5.200% |
1,572,170 (New Position) |
Filing History |